Knight Therapeutics Inc. (TSX:GUD)

Knight Therapeutics Income Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	450.09	371.3	328.2	293.56	243.48
Revenue Growth (YoY)	21.22%	13.13%	11.80%	20.57%	22.03%
Cost of Revenue	249.86	196.9	175.55	155.5	128.07
Gross Profit	200.23	174.41	152.65	138.06	115.41
Selling, General & Admin	124.11	99.35	83.69	88.62	74.38
Depreciation & Amortization Expenses	49.49	44.36	45.04	51.74	41.18
Research & Development	28.98	23.3	17.55	14.76	12.69
Other Operating Expenses	-	-	9.26	23.98	-
Total Operating Expenses	202.58	167.01	155.54	179.11	128.24
Operating Income	-2.35	7.4	-2.89	-41.04	-12.83
Interest Income	6.21	10.41	12.58	10.63	7.38
Interest Expense	-10.42	-9.22	-12.49	-6.6	-3.62
Other Non-Operating Income (Expense)	-0.14	-6.53	-19.19	-6.95	15.76
Total Non-Operating Income (Expense)	-4.35	-5.35	-19.1	-2.92	19.52
Pretax Income	-6.7	2.05	-21.99	-43.96	6.69
Net Income	-6.7	2.05	-21.99	-43.96	6.69
Net Income to Common	-6.7	2.05	-21.99	-43.96	6.69
Net Income Growth	-	-	-	-	-83.97%
Shares Outstanding (Basic)	100	101	107	115	124
Shares Outstanding (Diluted)	100	101	107	115	125
Shares Change (YoY)	-1.84%	-5.61%	-6.46%	-7.74%	-5.66%
EPS (Basic)	-0.05	0.04	-0.16	-0.26	0.13
EPS (Diluted)	-0.05	0.04	-0.16	-0.26	0.13
EPS Growth	-	-	-	-	-59.38%
Free Cash Flow	67.05	33.81	34.99	42.12	40.79
Free Cash Flow Growth	98.30%	-3.37%	-16.92%	3.26%	-
Free Cash Flow Per Share	0.67	0.33	0.33	0.37	0.33
Gross Margin	44.49%	46.97%	46.51%	47.03%	47.40%
Operating Margin	-0.52%	1.99%	-0.88%	-13.98%	-5.27%
Profit Margin	-1.49%	0.55%	-6.70%	-14.97%	2.75%
FCF Margin	14.90%	9.11%	10.66%	14.35%	16.75%
EBITDA	54.22	60.51	47.51	21.58	35.08
EBITDA Margin	12.05%	16.30%	14.48%	7.35%	14.41%
EBIT	-2.35	7.4	-2.89	-41.04	-12.83
EBIT Margin	-0.52%	1.99%	-0.88%	-13.98%	-5.27%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.